Provided by Tiger Trade Technology Pte. Ltd.

Crinetics Pharmaceuticals Inc.

84.69
0.0000
Post-market: 84.710.0167+0.02%19:30 EDT
Volume:2.02M
Turnover:170.83M
Market Cap:8.99B
PE:-16.84
High:84.77
Open:84.70
Low:84.69
Close:84.69
52wk High:84.80
52wk Low:29.63
Shares:106.10M
Float Shares:95.53M
Volume Ratio:0.53
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0290
EPS(LYR):-4.9500
ROE:-42.45%
ROA:-26.28%
PB:7.54
PE(LYR):-17.11

Loading ...

Crinetics says Phase 2 trial shows atumelnant cuts CAH androgen levels 67% while enabling glucocorticoid dose reduction

Reuters
·
Jun 15

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah) in Oral Presentation at Endo 2026

THOMSON REUTERS
·
Jun 15

Crinetics says two-year PATHFNDR extension data show oral Palsonify maintains IGF-1 control in acromegaly patients

Reuters
·
Jun 15

Crinetics Pharmaceuticals Price Target Maintained With a $95.00/Share by Citizens

Dow Jones
·
Jun 11

BUZZ-Crinetics will get more time after FDA setback for Camurus' rival drug, Piper Sandler says

Reuters
·
Jun 11

Crinetics to present up to 2-year PATHFNDR open-label extension data on oral acromegaly drug Palsonify at ENDO 2026

Reuters
·
Jun 02

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Q1 2026 Revenue Growth And Wider Net Loss

Simply Wall St.
·
May 16

Crinetics Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 16

Crinetics price target lowered to $88 from $89 at Evercore ISI

TIPRANKS
·
May 15

Crinetics Pharmaceuticals : Oppenheimer Cuts Target Price to $84 From $87

THOMSON REUTERS
·
May 11

Crinetics Pharmaceuticals Down Over 14%, on Pace for Largest Percent Decrease Since January 2025 -- Data Talk

Dow Jones
·
May 09

Crinetics Pharmaceuticals Is Maintained at Market Outperform by Citizens

Dow Jones
·
May 08

Stock Track | Crinetics Pharmaceuticals Plummets 5.73% Intraday Following Analyst Price Target Reduction

Stock Track
·
May 08

Crinetics price target lowered to $95 from $97 at Citizens

TIPRANKS
·
May 08

Earnings Flash (CRNX) Crinetics Pharmaceuticals Posts Q1 Loss $1.23 a Share, vs. FactSet Est of $1.22 Loss

MT Newswires Live
·
May 08

Crinetics Pharmaceuticals Q1 revenue jumps on Palsonify launch

Reuters
·
May 08

Crinetics Pharmaceuticals Q1 EPS $(1.23) Beats $(1.25) Estimate, Sales $10.306M Beat $8.512M Estimate

Benzinga Earnings
·
May 08

BRIEF-Crinetics Pharmaceuticals Q1 Net Income USD -127.845 Million

Reuters
·
May 08

Crinetics Pharmaceuticals Inc - Expects 2026 Gaap Operating Expenses $600 Mln-$650 Mln; Non-Gaap Operating Expenses $480 Mln-$520 Mln

THOMSON REUTERS
·
May 08

Crinetics Pharmaceuticals Q1 Revenue USD 10.306 Million

THOMSON REUTERS
·
May 08